[Variations in fecal microbiota of first episode schizophrenia associated with clinical assessment and serum metabolomics].

作者：X P Wang, Y Y Zhang, Tian-Lan Lu, Zhuoming Lu, Z W Kang, Yanhong Sun, W H Yue · 发表于：PubMed · 年份：2022 · DOI：10.19723/j.issn.1671-167x.2022.05.014 · 被引用次数：3 · 研究领域：Gut microbiota and health、Tryptophan and brain disorders、Metabolomics and Mass Spectrometry Studies

OBJECTIVE: To explore the role of the microbiota in drug naïve first-onset schizophrenia patients and to seek evidence from multidimensional longitudinal analyses of the intestinal microbiome and clinical phenotype with antipsychotic drugs (APDs) therapy. METHODS: In this study, 28 drug naïve first onset schizophrenia patients and age-, gender- and education-matched 29 healthy controls were included, and the patients were treated with APDs. We collected fecal and serum samples at baseline and after 6 weeks of treatment to identify the different microbiota strains and analyse their correlation with clinical symptoms and serum metabolites. The 16S rRNA genes of the gut microbiota were sequenced, and the diversity and relative abundance at the phylum and genus levels were analyzsed in detail. The PANSS score, BMI changed value, and serum metabolome were included in the data analyses. RESULTS: -proline, homovanillic acid, N-acetylserotonin, and vitamin B6. CONCLUSION: Our study found some microbiota features in schizophrenia patients and healthy controls, and several strains were correlated with APDs effects. Furthermore, the multiomics analysis implies the intermediate role of microbiota between antipsychotic effects and serum metabolites and provides new evidence to interpret the difference from multiple levels in the pathogenesis and pharmacological mechanism of schizophrenia.